Amgen Inc Conference Call from 2022 World Conference on Lung Cancer (WCLC) Transcript

Aug 08, 2022 / 04:00PM GMT

My name is Jason, and I will be your conference facilitator today for Amgen's conference call from the 2022 World Conference on Lung Cancer. (Operator Instructions).

I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.

David M. Reese - Amgen Inc. - EVP of Research & Development

Actually, Jason, this is David Reese, Head of Research and Development at Amgen. I'll be helping to host today's conference. We'll provide an oncology clinical update on some of our lung cancer programs, based on data that were presented here in Vienna at the World Conference on Lung Cancer over the last couple of days. We know there's a lot of interest in these data, and so we'll move into data summaries very quickly here.

Can we advance the slide, please? Here is our safe harbor statement and today's agenda. After very short remarks from me, Dr. Bob Li will present an update on the LUMAKRAS combination studies presented here, including both checkpoint inhibitor combinations as well as the SHP2 combination

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot